Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=29186721
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
n-3 Polyunsaturated Fatty Acids and Cardiovascular Disease: Principles,
Practices, Pitfalls, and Promises - A Contemporary Review
#MMPMID29186721
Kones R
; Howell S
; Rumana U
Med Princ Pract
2017[]; 26
(6
): 497-508
PMID29186721
show ga
Amidst voluminous literature, inconsistencies and opposing results have confused
rather than clarified cardiologists' ability to assess the potential benefits of
n-3 polyunsaturated fatty acids (n-3 PUFA). In perspective, there are common
themes that emerge from n-3 PUFA studies, even as imperfect as they may be. The
approach taken was to identify and unite these themes into a manageable,
cohesive, evidence-based, yet useful synthesis. In all reviews and meta-analyses,
the selection of component studies and assumptions influences outcomes. This
overarching principle must be combined with the totality of the data,
particularly when evidence is incompletely understood and gaps in knowledge must
be bridged. Both the older literature and the most recent rigorous meta-analyses
indicate that n-3 PUFA are highly pleiotropic agents with many documented
positive physiological effects. Concordance among preclinical, observational,
randomized clinical trials and meta-analyses is impressive. These agents have
modest, statistically significant benefits which accrue over time. Given their
favorable safety profile, a risk reduction of about 10% justifies their potential
use in cardiovascular disease.
|Cardiovascular Diseases/mortality/*prevention & control
[MESH]
|Coronary Disease/prevention & control
[MESH]
|Death, Sudden, Cardiac/prevention & control
[MESH]
free
free
free
